Home › Research › Health systems and care delivery
The “American (cancer) patients first” plan to reduce drug prices—A critical assessment
Hagop M. Kantarjian, Donald W. Light, Vivian Ho. American Journal of Hematology, 2018-09-16
Topic: Risk, prevention and care in population studies
Plain-language summary
Serious concerns over the rising cost of cancer drugs in the United States1-3 are increasing,4-9 following a decade during which prices rose from an average of less than $10 000/year to more than $170 000/year in 2017.10 Despite the drug industry's wish to be “part of the solution,” the problem continues to worsen.6 Between 1995 and 2013, the launch price of cancer drugs increased by 10%-12% every year.11 According to a March 2018 report, the Average Wholesale Prices of drugs increased at unprecedented rates.12 A study by Gordon and colleagues showed a 25% average annual price increase of drugs already on the market, despite competition.13 Cancer drugs spending doubled since 2013 and is expected to double again by 2022.14 This suggests that health care is different from other industries where traditional free market forces are effective in lowering prices, and that other measures are needed. Because of the current health care reimbursement environment,15, 16 Americans are now additionally burdened with higher insurance premiums, high out-of-pocket costs, high deductibles, and high co-pay prescription expenses.17-20 This strategy is based in part on a 1984 study by the RAND Corporation suggesting that when patients have “skin in the game,” health-care costs are reduced, because they choose the most economical options.21 This may have been true two decades ago, when the costs of care and drugs were more reasonable, and may be true today for primary care and minor medical conditions. Lower costs observed in recent times are not the result of patients choosing wisely, but because they abandon or delay treatment,22-25 which increases mortality.26 Today, cancer patients may pay 20%-30% out-of-pocket for prescription drug costs. The U.S. drug prices (and drug industry profiteering) result from pharmaceutical lobby-driven policies and regulations that prevent the federal government from negotiating effectively. It contributed to the current opioid tragedy in the U.S., which in 2017 caused the addiction of 3 million individuals and 70 000 + overdose deaths.78, 79 Advertisements may convince Americans to support pharma strategies that sustain high drug prices, as exemplified by the massive “Go Boldly” campaign, paid for by PhRMA, which delivers the subliminal message that if drug prices are controlled, discoveries that cure Alzheimer's disease and dementia will not happen.5, 6, 9 Requiring drug advertisements to include the price would pressure companies to be more
What this study adds
Evidence grade: Low
This paper critically assesses a plan to reduce cancer drug prices in the United States. Reported effect size: increased by 10%; 0.1%; 1.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kantarjian, H. M., Light, D. W., & Ho, V. (2018). The “American (cancer) patients first” plan to reduce drug prices—A critical assessment. American Journal of Hematology. https://doi.org/10.1002/ajh.25284
Vancouver
Kantarjian HM, Light DW, Ho V. The “American (cancer) patients first” plan to reduce drug prices—A critical assessment. American Journal of Hematology. 2018. doi:10.1002/ajh.25284. PMID: 30218454.
BibTeX
@article{kantarjian2018-30218454,
author = {Kantarjian, Hagop M. and Light, Donald W. and Ho, Vivian},
title = {{The “American (cancer) patients first” plan to reduce drug prices—A critical assessment}},
journal = {American Journal of Hematology},
year = {2018},
doi = {10.1002/ajh.25284},
pmid = {30218454},
url = {https://doi.org/10.1002/ajh.25284}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Serious concerns over the rising cost of cancer drugs in the United States1-3 are increasing,4-9 following a decade during which prices rose from an average of less than $10 000/year to more than $170 000/year in 2017.10 Despite the drug industry's wish to be “part of the solution,” the problem continues to worsen.6 Between 1995 and 2013, the launch price of cancer drugs increased by 10%-12% every year.11 According to a March 2018 report, the Average Wholesale Prices of drugs increased at unprecedented rates.12 A study by Gordon and colleagues showed a 25% average annual price increase of drugs already on the market, despite competition.13 Cancer drugs spending doubled since 2013 and is expected to double again by 2022.14 This suggests that health care is different from other industries where traditional free market forces are effective in lowering prices, and that other measures are needed.
- Because of the current health care reimbursement environment,15, 16 Americans are now additionally burdened with higher insurance premiums, high out-of-pocket costs, high deductibles, and high co-pay prescription expenses.17-20 This strategy is based in part on a 1984 study by the RAND Corporation suggesting that when patients have “skin in the game,” health-care costs are reduced, because they choose the most economical options.21 This may have been true two decades ago, when the costs of care and drugs were more reasonable, and may be true today for primary care and minor medical conditions.
- Lower costs observed in recent times are not the result of patients choosing wisely, but because they abandon or delay treatment,22-25 which increases mortality.26 Today, cancer patients may pay 20%-30% out-of-pocket for prescription drug costs.
- The U.S. drug prices (and drug industry profiteering) result from pharmaceutical lobby-driven policies and regulations that prevent the federal government from negotiating effectively.
- It contributed to the current opioid tragedy in the U.S., which in 2017 caused the addiction of 3 million individuals and 70 000 + overdose deaths.78, 79 Advertisements may convince Americans to support pharma strategies that sustain high drug prices, as exemplified by the massive “Go Boldly” campaign, paid for by PhRMA, which delivers the subliminal message that if drug prices are controlled, discoveries that cure Alzheimer's disease and dementia will not happen.5, 6, 9 Requiring drug advertisements to include the price would pressure companies to be more competitive, and would remind patients and the public of the hardships associated with high drug prices.
Why it matters
This paper critically assesses a plan to reduce cancer drug prices in the United States. It contains no information about treating, curing, or preventing Alzheimer's disease.
Study details
- Effect sizeincreased by 10%; 0.1%; 1.3%
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (American Journal of Hematology) |
| Journal's citation record | 2 / 4 | American Journal of Hematology: journal h-index 174 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 9 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.9 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Vivian Ho: h-index 29 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | The University of Texas MD Anderson Cancer Center: institution h-index 1,800 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30218454) |
| Free to read | 2 / 2 | Free to read |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/ajh.25284
- PubMed: 30218454
- Original source →
- Free full text: American Journal of Hematology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.